ERYTECH Pharma(ERYP)高管介绍_美股行情_同花顺金融网

来自 : stockpage.10jqka.com.cn/ERYP/m 发布时间：2021-03-24

Luc Dochez，他曾一直担任我们的首席商务官，负责业务发展的高级副总裁（2008年11月以来）。他在生物技术产业有着超过15年的经验。加入Prosensa公司之前，他曾担任Arthur D. Little的生物技术实习顾问（从1998年到2001年）、Methexis Genomics公司的业务发展董事（从2001年到2002年）、TiGenix公司的业务拓展副总裁（从2002年到2008年），以及TiGenix公司的总裁（从2007年到2008年）。他持有the University of Leuven的药学博士学位、the same university的商业经济学研究生学位，以及Vlerick Management School的工商管理硕士学位。他目前是Ovizio公司的监事会独立成员。

Luc Dochez has served as a member of our board of directors since 2015. Mr. Dochez is currently a venture partner at DROIA N.V., a position he has held since October 2018. Prior to then, he served as Chief Executive Officer of Tusk Therapeutics Ltd., a private company focused on developing novel immuno-oncology products, from March 2015 until its acquisition by Roche in September 2018. Mr. Dochez has over 15 years of experience in the biotechnology industry. He served as the Chief Business Officer and Senior Vice President of Business Development of Prosensa Holding N.V., a biotechnology company, from November 2008 until its acquisition by BioMarin Pharmaceutical Inc. in January 2015. Before joining Prosensa, he served as Vice President of Business Development at TiGenix, Director Business Development at Methexis Genomics, and a consultant at Arthur D. Little. Mr. Dochez is a board member of Pharvaris BV, a Dutch company focused on rare diseases, as well as Bioncotech Therapeutics SL, a Spanish oncology company. He serves as an advisor to EverImmune S.A., a French microbiome company, and is an expert member of the Investment Committee of QBIC II, a Belgian seed investment fund. Mr. Dochez holds a Pharm.D. degree and a postgraduate degree in business economics from the University of Leuven Belgium and an M.B.A. degree from Vlerick Management School (Belgium). Luc Dochez，他曾一直担任我们的首席商务官，负责业务发展的高级副总裁（2008年11月以来）。他在生物技术产业有着超过15年的经验。加入Prosensa公司之前，他曾担任Arthur D. Little的生物技术实习顾问（从1998年到2001年）、Methexis Genomics公司的业务发展董事（从2001年到2002年）、TiGenix公司的业务拓展副总裁（从2002年到2008年），以及TiGenix公司的总裁（从2007年到2008年）。他持有the University of Leuven的药学博士学位、the same university的商业经济学研究生学位，以及Vlerick Management School的工商管理硕士学位。他目前是Ovizio公司的监事会独立成员。 Luc Dochez has served as a member of our board of directors since 2015. Mr. Dochez is currently a venture partner at DROIA N.V., a position he has held since October 2018. Prior to then, he served as Chief Executive Officer of Tusk Therapeutics Ltd., a private company focused on developing novel immuno-oncology products, from March 2015 until its acquisition by Roche in September 2018. Mr. Dochez has over 15 years of experience in the biotechnology industry. He served as the Chief Business Officer and Senior Vice President of Business Development of Prosensa Holding N.V., a biotechnology company, from November 2008 until its acquisition by BioMarin Pharmaceutical Inc. in January 2015. Before joining Prosensa, he served as Vice President of Business Development at TiGenix, Director Business Development at Methexis Genomics, and a consultant at Arthur D. Little. Mr. Dochez is a board member of Pharvaris BV, a Dutch company focused on rare diseases, as well as Bioncotech Therapeutics SL, a Spanish oncology company. He serves as an advisor to EverImmune S.A., a French microbiome company, and is an expert member of the Investment Committee of QBIC II, a Belgian seed investment fund. Mr. Dochez holds a Pharm.D. degree and a postgraduate degree in business economics from the University of Leuven Belgium and an M.B.A. degree from Vlerick Management School (Belgium).